Tags

Type your tag names separated by a space and hit enter

Long-term follow-up of patients undergoing allogeneic bone marrow transplantation for acute myeloid leukemia in first complete remission after cyclophosphamide-total body irradiation and cyclosporine.
Bone Marrow Transplant. 1996 Oct; 18(4):741-6.BM

Abstract

Eighty-five patients (median age 28 years) with acute myeloid leukemia (AML) in first remission underwent allogeneic bone marrow transplantation (BMT) from HLA-identical siblings between 1978 and 1987 after cyclophosphamide and single-fraction total body irradiation with cyclosporine for graft-versus-host disease (GVHD) prophylaxis. The actuarial probabilities of development of acute and chronic GVHD were 57% and 47%, respectively. Twenty-six patients died of transplant-related complications at a median of 3.5 months, and two of unrelated causes. Seventeen patients relapsed at a median of 6.5 months. Forty patients were alive and well at 74-197 months (median 157) after BMT; seven (18%) with limited chronic GVHD requiring therapy. The actuarial 10-year probabilities of transplant-related death, relapse, and disease-free survival were 33%, 25% and 48% respectively. In multivariate analysis, infusion of a lower cell dose, development of GVHD, and age > 35 years were associated with increased transplant-related mortality, donor-recipient ABO incompatibility with a lower relapse rate, and age > 35 years and a lower cell dose with poorer disease-free survival. We conclude that with long-term follow-up, allografting in AML after cyclophosphamide-TBI and cyclosporine has resulted in disease-free survival that is comparable to most currently reported series. Patients who are alive and well 3-4 years after BMT have excellent prospects of long-term survival.

Authors+Show Affiliations

Leukaemia Unit, Royal Marsden Hospital, Surrey, UK.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article

Language

eng

PubMed ID

8899189

Citation

Mehta, J, et al. "Long-term Follow-up of Patients Undergoing Allogeneic Bone Marrow Transplantation for Acute Myeloid Leukemia in First Complete Remission After Cyclophosphamide-total Body Irradiation and Cyclosporine." Bone Marrow Transplantation, vol. 18, no. 4, 1996, pp. 741-6.
Mehta J, Powles R, Treleaven J, et al. Long-term follow-up of patients undergoing allogeneic bone marrow transplantation for acute myeloid leukemia in first complete remission after cyclophosphamide-total body irradiation and cyclosporine. Bone Marrow Transplant. 1996;18(4):741-6.
Mehta, J., Powles, R., Treleaven, J., Horton, C., Tait, D., Meller, S., Pinkerton, C. R., Middleton, G., Eisen, T., & Singhal, S. (1996). Long-term follow-up of patients undergoing allogeneic bone marrow transplantation for acute myeloid leukemia in first complete remission after cyclophosphamide-total body irradiation and cyclosporine. Bone Marrow Transplantation, 18(4), 741-6.
Mehta J, et al. Long-term Follow-up of Patients Undergoing Allogeneic Bone Marrow Transplantation for Acute Myeloid Leukemia in First Complete Remission After Cyclophosphamide-total Body Irradiation and Cyclosporine. Bone Marrow Transplant. 1996;18(4):741-6. PubMed PMID: 8899189.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Long-term follow-up of patients undergoing allogeneic bone marrow transplantation for acute myeloid leukemia in first complete remission after cyclophosphamide-total body irradiation and cyclosporine. AU - Mehta,J, AU - Powles,R, AU - Treleaven,J, AU - Horton,C, AU - Tait,D, AU - Meller,S, AU - Pinkerton,C R, AU - Middleton,G, AU - Eisen,T, AU - Singhal,S, PY - 1996/10/1/pubmed PY - 1996/10/1/medline PY - 1996/10/1/entrez SP - 741 EP - 6 JF - Bone marrow transplantation JO - Bone Marrow Transplant VL - 18 IS - 4 N2 - Eighty-five patients (median age 28 years) with acute myeloid leukemia (AML) in first remission underwent allogeneic bone marrow transplantation (BMT) from HLA-identical siblings between 1978 and 1987 after cyclophosphamide and single-fraction total body irradiation with cyclosporine for graft-versus-host disease (GVHD) prophylaxis. The actuarial probabilities of development of acute and chronic GVHD were 57% and 47%, respectively. Twenty-six patients died of transplant-related complications at a median of 3.5 months, and two of unrelated causes. Seventeen patients relapsed at a median of 6.5 months. Forty patients were alive and well at 74-197 months (median 157) after BMT; seven (18%) with limited chronic GVHD requiring therapy. The actuarial 10-year probabilities of transplant-related death, relapse, and disease-free survival were 33%, 25% and 48% respectively. In multivariate analysis, infusion of a lower cell dose, development of GVHD, and age > 35 years were associated with increased transplant-related mortality, donor-recipient ABO incompatibility with a lower relapse rate, and age > 35 years and a lower cell dose with poorer disease-free survival. We conclude that with long-term follow-up, allografting in AML after cyclophosphamide-TBI and cyclosporine has resulted in disease-free survival that is comparable to most currently reported series. Patients who are alive and well 3-4 years after BMT have excellent prospects of long-term survival. SN - 0268-3369 UR - https://www.unboundmedicine.com/medline/citation/8899189/Long_term_follow_up_of_patients_undergoing_allogeneic_bone_marrow_transplantation_for_acute_myeloid_leukemia_in_first_complete_remission_after_cyclophosphamide_total_body_irradiation_and_cyclosporine_ L2 - http://www.diseaseinfosearch.org/result/4195 DB - PRIME DP - Unbound Medicine ER -